Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products not yet catalogued.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
No credible adverse media (lawsuits, regulator action, misconduct or financial distress) involving Imprivata found in HSH's search of the last 24 months.
Jun 2026: Imprivata issued a security advisory for its Enterprise Access Management appliances covering several critical (up to CVSS 9.8) and high-severity flaws, with hotfixes for versions 24.2-26.1; it said there was no evidence of exploitation. NHS DSPT status not yet checked.
Identity and access security software supplier; no regulatory or clinical safety actions found in the last 24 months.
Nov 2025: NHS Wales Shared Services Partnership awarded a £100,577 contract (via reseller Softcat) for Imprivata OneSign subscriptions and support at Swansea Bay University Health Board. No troubled implementations or disputes found in HSH's search of the last 24 months.
No competitors linked yet.